864P - External validation of a prognostic score in first-line metastastic castration-resistant prostate cancer (mCRPC)

864P - External validation of a prognostic score in first-line metastastic castration-resistant prostate cancer (mCRPC)

Due to improved outcome in mCRPC, most prognostic models may not reflect the current treatment landscape. Recently, Armstrong et al (Ann Oncol 2018) published a prognostic model based on the phase III PREVAIL trial. We applied the Armstrong prognostic model to patients (pts) treated in the COU-AA-30...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2019-10, Vol.30, p.v337-v338
Hauptverfasser: Lorente, D., Mejorada, R Lozano, De de Rueda, G AVelasco Oria, Hernandez, A Sanchez, Aliaga, M Rodrigo, Iglesias, Á Sánchez, Campayo, M de Julián, Campos, F Lopez, Laorden, N Romero, Castro, E., Hidalgo, D Olmos
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Due to improved outcome in mCRPC, most prognostic models may not reflect the current treatment landscape. Recently, Armstrong et al (Ann Oncol 2018) published a prognostic model based on the phase III PREVAIL trial. We applied the Armstrong prognostic model to patients (pts) treated in the COU-AA-302 trial. Variables included in the model: albumin, ALP, Hb, LDH, NLR, number of bone metastases, pain, pattern of spread, PSA, time from diagnosis. Pts were categorized into low (
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdz248.021